The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
Study Details
Study Description
Brief Summary
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein) in first-degree relatives of patients with multiple myeloma in China population, and establish a prospective cohort of individuals with monoclonal gammopathy of undetermined significance (MGUS), a precursor conditions to multiple myeloma. We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The CHAPERONE study aims to assess the clinical significance of screening for monoclonal gammopathy in first-degree relatives of patients with multiple myeloma in China.
The main objectives it aims to answer are:
-
Main research objectives: To study the prevalence of MGUS, the time of disease progression, and its influencing factors in first-degree relatives of multiple myeloma patients in China.
-
Secondary study objective: To explore the clinical/genomic/epigenetic features, survival, and quality of life of MGUS patients in first-degree relatives of multiple myeloma patients in China.
All participants will receive M-protein screening by serum electrophoresis. Individuals with detected M-protein will undergo further diagnostic tests, and patients with MGUS will be carefully assessed and followed up.
Study Design
Outcome Measures
Primary Outcome Measures
- The prevalence of monoclonal gammopathy of undetermined significance (MGUS) in MM first-degree relatives [2 Years]
The prevalence of MGUS in MM first-degree relatives: defined as the proportion of MGUS cases among the total population ( MM first-degree relatives) receiving M-protein screening
- Time to progression (TTP) from MGUS to overt multiple myeloma [10 Years]
The time interval between the first diagnosis of MGUS and the first recording of participants and the diagnosis of myeloma. For participants who did not record disease progression to myeloma, the last follow-up date was used as the cut-off date.
Secondary Outcome Measures
- Overall survival of MGUS patients [10 Years]
The time interval between the first diagnosis of MGUS and the recording of death from any cause. For participants whose death is not recorded, the cut-off date is the most recent point at which it is known that the participant is still alive.
- Quality of life (QoL) of MGUS patients [10 Years]
QoL evaluation was performed using the Patient Self-Rating Scale (EORTC QLQ - C30) during the case screening period and at each follow-up period.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female over the age of 18;
-
First-degree relatives (including parents, children, and biological siblings) have multiple myeloma diagnosed by the International Myeloma Working Group (IMWG) Myeloma Diagnostic Criteria;
-
Understand the purpose and procedure of this trial and voluntarily participate in this screening study;
-
Participants should be willing and able to follow the study follow-up plan and other protocol requirements.
Exclusion Criteria:
Patients with a known diagnosis of plasma cell diseases, such as MGUS, smoldering myeloma (SMM), or multiple myeloma
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Zhongshan Hospital，Fudan University | Shanghai | Shanghai | China | 200032 |
Sponsors and Collaborators
- Shanghai Zhongshan Hospital
Investigators
- Principal Investigator: Peng Liu, PhD, MD, Fudan University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHAPERONE